Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Drug

GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial

Fineline Cube Jul 8, 2022

Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...

Company Deals Digital

ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor

Fineline Cube Jul 7, 2022

Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...

Company Deals

Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment

Fineline Cube Jul 7, 2022

China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Medical Device

Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product

Fineline Cube Jul 7, 2022

Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD

Fineline Cube Jul 7, 2022

Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics

Fineline Cube Jul 7, 2022

China-based gene editing specialist ZhuHai GeneRulor Medical Technology Co., Ltd. reportedly raised “tens of millions”...

Company Drug

Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China

Fineline Cube Jul 7, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced the commercial launch in China of the anti-COVID-19...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment

Fineline Cube Jul 7, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the Biologics License Application (BLA) for...

Company Deals

I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal

Fineline Cube Jul 7, 2022

China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...

Company Deals

Adicon Holdings and Guardant Health Partner on Genomic Profiling in China

Fineline Cube Jul 7, 2022

China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...

Company Deals

BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development

Fineline Cube Jul 7, 2022

China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with...

Company Deals

PackGene and SineuGene Partner on ALS Gene Therapy Research

Fineline Cube Jul 7, 2022

China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus...

Policy / Regulatory

China Establishes Leadership Group to Combat Drug-Related Crimes

Fineline Cube Jul 7, 2022

China’s State Council executive body released a notification regarding the establishment of a leadership group...

Company Deals Digital

Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push

Fineline Cube Jul 7, 2022

Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study

Fineline Cube Jul 7, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Company Drug

Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study

Fineline Cube Jul 6, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Drug

GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome

Fineline Cube Jul 6, 2022

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from...

Company Drug

Inmagene and HutchMed Dose First Patient in IMG-007 Global Phase I Study

Fineline Cube Jul 6, 2022

China-based Inmagene Biopharmaceuticals and HutchMed (NASDAQ: HCM, HKG: 0013) announced the completion of first patient...

Company Deals

ClinChoice Raises USD 150M in Funding Led by Legend Capital for Expansion

Fineline Cube Jul 6, 2022

Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a...

Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review

Fineline Cube Jul 6, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...

Posts pagination

1 … 703 704 705 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.